Clinical Scorecard: Combining Single-Cell and Spatial Transcriptomics Uncovers Glycolytic Diversity and NEK6-Driven Advancement in Colorectal Cancer

At a Glance

Key Highlights

• Identification of three distinct malignant subtypes in CRC, with Glycolysis-C1 showing a high-glycolytic state.
• Glycolysis-C1 cells act as a signaling hub, influencing immune cell behavior through MIF-CD44 interactions.
• NEK6 identified as a candidate gene linked to CRC risk and poor prognosis.
• Functional assays demonstrated that NEK6 knockdown reduces CRC cell proliferation and glycolysis.
• Study integrates scRNA-seq, spatial transcriptomics, and Mendelian randomization for comprehensive analysis.

Guideline-Based Recommendations

Diagnosis

• Utilize single-cell RNA sequencing and spatial transcriptomics to assess tumor heterogeneity.

Management

• Consider NEK6 as a potential therapeutic target in high-glycolytic CRC subtypes.

Monitoring & Follow-up

• Monitor NEK6 expression levels as a prognostic indicator in CRC patients.

Risks

• High NEK6 expression correlates with an immunosuppressive tumor microenvironment and poor patient outcomes.

Patient & Prescribing Data

Patients diagnosed with advanced colorectal cancer exhibiting metabolic reprogramming.

Targeting NEK6 may provide a novel therapeutic strategy for CRC management.

Clinical Best Practices

• Incorporate multi-omics approaches to understand tumor biology and inform treatment strategies.
• Evaluate cell-cell communication networks to identify potential therapeutic interventions.

References

• GSE161277